We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library ... Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease. Show more
Azitra will present two oral presentations at ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 related to ATR-12, Azitra’s candidate for Netherton syndrome Topical...
ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 SID (Society of Investigative Dermatology) Dallas, TX, May 15-18, 2024 ASCO (American Society of Clinical...
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full...
Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0285 | 15 | 0.19 | 0.24 | 0.187 | 868104 | 0.21668583 | CS |
4 | 0.0078 | 3.70194589464 | 0.2107 | 0.26 | 0.1605 | 771318 | 0.20672915 | CS |
12 | -0.9315 | -81 | 1.15 | 1.2699 | 0.1605 | 718631 | 0.23836423 | CS |
26 | -1.4315 | -86.7575757576 | 1.65 | 2.28 | 0.1605 | 348546 | 0.29279851 | CS |
52 | -4.0415 | -94.8708920188 | 4.26 | 5.18 | 0.1605 | 211520 | 0.43743045 | CS |
156 | -4.0415 | -94.8708920188 | 4.26 | 5.18 | 0.1605 | 211520 | 0.43743045 | CS |
260 | -4.0415 | -94.8708920188 | 4.26 | 5.18 | 0.1605 | 211520 | 0.43743045 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions